Cancer Genetics, a Rutherford-based clinical diagnostic center that specializes in difficult-to-diagnose cancers, said on Monday its board appointed John Pappajohn as chairman, effective immediately.

Pappajohn, a shareholder of Cancer Genetics, has been involved with more than 100 start-up companies and served as a director of more than 40 public companies, according to a Cancer Genetics news release.

Pappajohn will replace Cancer Genetics founder Raju S.K. Chaganti as chairman. Chaganti will still "play an important role" at Cancer Genetics and will continue to manage the company's scientific advisory board, the news release said.

""The contributions of Dr. Chaganti and his world-class research team in developing the technology behind our unique personalized oncology tests, matched with the disciplined and focused leadership of our CEO Panna Sharma, has positioned the Company for strong future growth," Pappajohn said in the news release. "Our 2013 double-digit revenue growth, our joint venture with Mayo Clinic, and the commercial roll out of five proprietary tests, has already put CGI in an industry-leading position. I plan to help the Company build upon that success."

Cancer Genetics shares rose 39 cents, or 2.89 percent, to $13.89 at 2:56 p.m. in intraday trading Monday on the Nasdaq Stock Market. The company went public in April.

Email: wyrich@northjersey.com Twitter: @AndrewWyrich

Original post:
Rutherford-based Cancer Genetics appoints new chairman

Comments are closed.